Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05618925 · ClinicalTrials.gov registry record · Phase 1
Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma
A Phase 1 study of Non Hodgkin's Lymphoma Refractory/Relapsed, sponsored by ImmunityBio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT05618925 is a Phase 1 study of Non Hodgkin's Lymphoma Refractory/Relapsed that is actively recruiting participants, run by ImmunityBio. The registered enrollment target is 20 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT05618925, a Phase 1 study of Non Hodgkin's Lymphoma Refractory/Relapsed, is actively recruiting participants, sponsored by ImmunityBio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
Open-label, Phase 1 Study of CD19 t-haNK as a Single Agent and in Combination With an IL-15 Superagonist (N-803) and Rituximab in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma. Up to 20 subjects will be enrolled and randomized 1:1 to 1 of 2 cohorts, as outlined below. The initial 3 subjects will be sequentially enrolled in a staggered fashion, with a 7 day interval between each subject to enable the capture and monitoring of any acute and subacute toxicities.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Rituximab
- DRUG N803
- BIOLOGICAL CD19t-haNK suspension
Study Locations (2)
California
- Hoag Memorial Hospital - Newport Beach
Texas
- Texas Oncology - Tyler
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-08-22 |
| Est. Completion | 2027-03-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05618925
The ClinicalTrials.gov registry entry for NCT05618925 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunityBio, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non Hodgkin's Lymphoma Refractory/Relapsed appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT05618925 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Texas.
Frequently Asked Questions
What is clinical trial NCT05618925 about?
NCT05618925 is a clinical study titled "Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma". Open-label, Phase 1 Study of CD19 t-haNK as a Single Agent and in Combination With an IL-15 Superagonist (N-803) and Rituximab in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma. Up to 20 subjects will be enrolled and randomized 1:1 to 1 of 2 cohorts, as outlined below. The initial 3 subjects...
What is the current status of trial NCT05618925?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-08-22. Estimated completion is 2027-03-15.
What conditions does trial NCT05618925 study?
This clinical trial studies the following conditions: Non Hodgkin's Lymphoma Refractory/Relapsed.
What interventions are being tested in trial NCT05618925?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Rituximab (DRUG), N803 (DRUG), CD19t-haNK suspension (BIOLOGICAL).
Who is sponsoring clinical trial NCT05618925?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05618925 being conducted?
This trial has 2 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.